IShares Genomics Ownership
| IDNA Etf | USD 24.08 0.53 2.15% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
IShares |
IShares Etf Ownership Analysis
IShares Genomics is is formed as Regulated Investment Company in the United States. ETF is managed and operated by State Street Bank and Trust Company. The fund has 62 constituents across multiple sectors and instustries. The fund charges 0.47 percent management fee with a total expences of 0.47 percent of total asset. The fund retains 99.56% of assets under management (AUM) in equities. iShares Genomics Imm last dividend was 0.24 per share. The fund generally will invest at least 80 percent of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20 percent of its assets in certain futures, options and swap contracts, cash and cash equivalents. Genomics Immunology is traded on NYSEARCA Exchange in the United States. To learn more about iShares Genomics Immunology call the company at NA.Sector Exposure (%)
Investors will always prefer to have their portfolios divercified against different sectors. The broad sector allocation increases the possibility of making a profit or at least avoiding a loss. However, this may also reduce the expected return on IShares Etf. Generally, it depends on diversification level and type but usually, the broader the sector allocation, the less risk can be expected from holding IShares Genomics , and the less return is expected.
Currency Exposure (%)
Investment Allocations (%)
Top Etf Constituents
| ARRY | Array Technologies | Stock | |
| ALNY | Alnylam Pharmaceuticals | Stock | |
| BMY | Bristol Myers Squibb | Stock | |
| FGEN | FibroGen | Stock | |
| GEN | Gen Digital | Stock | |
| TWST | Twist Bioscience Corp | Stock | |
| SRPT | Sarepta Therapeutics | Stock | |
| SGEN | Seagen Inc | Stock | |
| ROG | Rogers | Stock | |
| REGN | Regeneron Pharmaceuticals | Stock | |
| NTLA | Intellia Therapeutics | Stock | |
| MRVI | Maravai Lifesciences Holdings | Stock | |
| MRTX | Mirati Ther | Stock | |
| MRNA | Moderna | Stock | |
| IOVA | Iovance Biotherapeutics | Stock | |
| INO | Inovio Pharmaceuticals | Stock | |
| GMAB | Genmab AS | Stock | |
| GILD | Gilead Sciences | Stock | |
| FATE | Fate Therapeutics | Stock | |
| EXEL | Exelixis | Stock | |
| CRSP | Crispr Therapeutics AG | Stock | |
| BPMC | Blueprint Medicines Corp | Stock | |
| BLUE | Bluebird bio | Stock | |
| BEAM | Beam Therapeutics | Stock |
IShares Genomics Outstanding Bonds
IShares Genomics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. iShares Genomics Imm uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most IShares bonds can be classified according to their maturity, which is the date when iShares Genomics Immunology has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether iShares Genomics Imm offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of IShares Genomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ishares Genomics Immunology Etf. Outlined below are crucial reports that will aid in making a well-informed decision on Ishares Genomics Immunology Etf:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iShares Genomics Immunology. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
The market value of iShares Genomics Imm is measured differently than its book value, which is the value of IShares that is recorded on the company's balance sheet. Investors also form their own opinion of IShares Genomics' value that differs from its market value or its book value, called intrinsic value, which is IShares Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IShares Genomics' market value can be influenced by many factors that don't directly affect IShares Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IShares Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if IShares Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IShares Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.